New hope for myeloma: experimental drug takes on standard combo
NCT ID NCT07452198
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing a new drug called GR1803 against a standard three-drug combination (daratumumab, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back after 1 to 3 prior treatments. About 358 participants will be randomly assigned to receive either GR1803 or the standard combo. The main goal is to see which treatment keeps the cancer from growing longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GR1803 injection (a drug given intravenously)
What this could lead to
If GR1803 works better than the current standard, it could offer a new treatment option for people with multiple myeloma that has come back after earlier therapies.
What could go wrong
This is an early Phase 3 trial, so results are not yet known. The new drug may not be more effective or could have unexpected side effects compared to the existing combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••